Navigation Links
Indevus Announces Management Changes
Date:6/12/2008

ions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly, and a biodegradable ureteral stent used in association with the adjunctive treatment of kidney stones.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
2. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
3. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
4. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
5. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
6. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
7. Indevus Announces Allergan as New Partner for SANCTURA Brand
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... Chairman, Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, ... JASIS on September 5, 2014. JASIS , Asia’s ... September 3-5, 2014, in Makuhari Messe, Japan. , ... New Tools for Bioanalysis from Single Molecules to Single ...
(Date:8/29/2014)... 2014 A major challenge before new ... dense realm of Boston-Cambridge, is gaining visibility that can ... Sherley, the Director of Boston’s Adult Stem Cell Technology ... national visibility of his company an important priority since ... addition to a social media marketing campaign ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides users ... said Mark Tess, PhD, Mycotoxin Product Manager for Charm Sciences. ... USDA-GIPSA inspection agencies that have a need to detect aflatoxin ... a matter of minutes with nothing but our equipment and ... grain before accepting it, but they no longer have to ...
(Date:8/28/2014)... 2014  Next month, executives from clinical trial marketing firm ... beginning with Patient-Centered Clinical Trials 2014 , to be ... , September 4-5. Patient recruitment experts Bonnie A. ... will share insights on the benefits of employing an ... – from media to mobile apps – can be used ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4BBK Worldwide Leads Sessions at Key September Events 2
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced today ... up to $185 million in exchange for rights ... American sales of Lexiscan(TM),(regadenoson) injection. CV Therapeutics received ... receive a potential future milestone payment,of $10 million., ...
... and Families, EMERYVILLE, Calif., April 15 ... two new health care areas designed to,soothe patients ... to offer health resources. The Carol Ann,Read Breast ... procedures, all in one location, for the quickest ...
... April 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ONC, ... Dr. Anders,Kolb of the Nemours Center for Childhood ... Pediatric Sarcomas" was,presented today at the American Association ... being held in San Diego, California from,April 12-16, ...
Cached Biology Technology:CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 2CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 3Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center 2Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center 3Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting 2
(Date:8/28/2014)... is pleased to announce the selection of Dr. Fred ... Membership acknowledges those who have served ESA for at ... of the Society that has reached an extraordinary level. ... Governing Board and then voted on by the ESA ... Ceremony at Entomology 2014, ESA,s Annual Meeting in Portland, ...
(Date:8/28/2014)... reports that an expansion of marine protected areas is ... functions. According to investigators from the Wildlife Conservation ... have focused on saving the largest numbers of species, ... key and difficult-to-replace ecological functions. , Many ... fish species that also are food for millions of ...
(Date:8/28/2014)... for your neighbors than traditional cigarettes, but still ... new study from USC. , Scientists studying secondhand ... in exposure to harmful particles, with close-to-zero exposure ... some harmful metals in second-hand e-cigarette smoke were ... smoke contains high levels of polycyclic aromatic hydrocarbons ...
Breaking Biology News(10 mins):Fred Baxendale selected as Honorary Member of the Entomological Society of America 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2Second-hand e-cig smoke compared to regular cigarette smoke 2
... The results of a recent study by the University of ... there was a unexpected increase in hydrocarbon levels along the ... Worsened in previous years by works to remove the wreck, ... 2006 along with numerous forest fires., On 19th November 2002 ...
... This press release is available in ... of the University of Montreal,s Department of Chemistry have discovered ... contamination of our water by sewers. " E coli ... of fecal pollution of our water from storm water discharge, ...
... - Researchers are making progress in developing a system ... technology that could be used to diagnose human disease ... an instrument called an atomic force microscope to study ... method,s potentially broad applications, said Arvind Raman, a Purdue ...
Cached Biology News:Hydrocarbon pollution along the coast of Galicia shot up five years after the Prestige oil spill 2Chemistry professor links feces and caffeine 2New medical, research tool possible by probing cell mechanics 2
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human SCP3 Affinity Purified Polyclonal Ab Keywords: Spermatogenesis, meiosis Protein Family: Cell Cycle...
Homo sapiens alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5), mRNA....
Human Rad1 MAb (Clone 33)...
Biology Products: